99 related articles for article (PubMed ID: 15160313)
1. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Miyazaki S
J Infect Chemother; 2004 Apr; 10(2):135. PubMed ID: 15160313
[No Abstract] [Full Text] [Related]
2. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa.
Yamada K; Yamamoto Y; Yanagihara K; Araki N; Harada Y; Morinaga Y; Izumikawa K; Kakeya H; Hasegawa H; Kohno S; Kamihira S
J Infect Chemother; 2012 Aug; 18(4):472-8. PubMed ID: 22215228
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series.
Delfino E; Fucile C; Del Bono V; Marchese A; Marini V; Coppo E; Casciaro R; Minicucci L; Giacobbe DR; Martelli A; Viscoli C; Mattioli F
New Microbiol; 2018 Jan; 41(1):47-51. PubMed ID: 29313863
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
10. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
[TBL] [Abstract][Full Text] [Related]
11. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
[TBL] [Abstract][Full Text] [Related]
12. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
13. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
Kristoffersson AN; David-Pierson P; Parrott NJ; Kuhlmann O; Lave T; Friberg LE; Nielsen EI
Pharm Res; 2016 May; 33(5):1115-25. PubMed ID: 26786016
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis.
Juan C
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Dec; 37(10):623-625. PubMed ID: 31611061
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.
Hengzhuang W; Høiby N; Ciofu O
Methods Mol Biol; 2014; 1147():239-54. PubMed ID: 24664838
[TBL] [Abstract][Full Text] [Related]
16. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
[TBL] [Abstract][Full Text] [Related]
18. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
19. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
[TBL] [Abstract][Full Text] [Related]
20. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.
Tam VH; Ledesma KR; Schilling AN; Lim TP; Yuan Z; Ghose R; Lewis RE
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):427-33. PubMed ID: 19631096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
